By focusing on receptor or ligand checkpoint proteins to inhibit immunosuppressive tumor signaling, such as programmed cell death 1 (PD-1), PD-1 ligand 1 (PDL1), and cytotoxic T lymphocyte antigen 4 (CTLA-4), ICIs restore the anticancer immune response [13]. Here, PDCD1 is linked to neoplasm.